GT BIOPHARMA, INC. Proceeds from Issuance or Sale of Equity
GT BIOPHARMA, INC. (GTBP) reported Proceeds from Issuance or Sale of Equity of $616.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-15.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2026-03-06
- GT BIOPHARMA, INC. proceeds from issuance or sale of equity for the quarter ending 2025-03-31 was $616.00K.
- GT BIOPHARMA, INC. proceeds from issuance or sale of equity for the quarter ending 2024-12-31 was $0.00.
- GT BIOPHARMA, INC. proceeds from issuance or sale of equity for the quarter ending 2024-09-30 was $0.00.
- GT BIOPHARMA, INC. proceeds from issuance or sale of equity for the quarter ending 2023-12-31 was $0.00.
- GT BIOPHARMA, INC. proceeds from issuance or sale of equity for fiscal 2024 was $2.98M, a 52.52% decline from fiscal 2023.
- GT BIOPHARMA, INC. proceeds from issuance or sale of equity for fiscal 2023 was $6.27M.
| Period end | Proceeds from Issuance or Sale of Equity 3 month | Proceeds from Issuance or Sale of Equity 6 month | Proceeds from Issuance or Sale of Equity 9 month | Proceeds from Issuance or Sale of Equity 12 month |
|---|---|---|---|---|
| 2025-03-31 | $616.00K 10-Q · filed 2025-05-15 | $616.00K derived: sum of 2 quarters · filed 2026-03-02 | $616.00K derived: sum of 3 quarters · filed 2026-03-06 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-06 | $2.98M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2026-03-06 | $2.98M 10-Q/A · filed 2026-03-06 | ||
| 2024-06-30 | $2.98M 10-Q/A · filed 2026-03-06 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $0.00 derived: sum of 2 quarters · filed 2025-02-21 | $0.00 derived: sum of 3 quarters · filed 2025-02-21 | $6.27M 10-K · filed 2025-02-21 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $6.27M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $6.27M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $6.27M 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |